The EMA’s CHMP recommended eight new medicines in its September outlook, including two ovarian cancer therapies and a potential first oral option for hidradenitis suppurativa. The committee also issued positive opinions for additional therapies and label expansions as part of its monthly review cycle. For developers, CHMP backing is a key step toward potential EU-wide approvals, particularly when it involves category-defining firsts such as the oral route for a chronic inflammatory disease. For clinicians and payers, the recommendations provide a near-term signal for where treatment options may expand once finalized through the EU process. The CHMP calendar matters for pipeline planning across oncology and immunology, as developers align late-stage readouts and regulatory submissions around EMA review timing.